Radiation oncology firm Accuray has received clearance to market its Radixact X9 radiation therapy system in India.
The Atomic Energy Regulatory Board (AERB) Type Approval states that the device measures up to established safety standards, and it will allow Accuray to sell this next-generation TomoTherapy platform in India, the company said.
Radixact X9 is integrated into Accuray's Precision treatment planning system and iDMS data management system. It features such tools as CTrue iterative reconstruction image guidance software, which improves soft-tissue contrast and reduces noise; PreciseART adaptive radiation therapy software, which helps clinicians monitor each patient and adapt treatment plans; and the PreciseRTX retreatment option, which automates the planning process for retreatment, according to the firm.
